Efficacy and safety of lisinopril for mild childhood IgA nephropathy: A pilot study

Koichi Nakanishi, Kzumoto Iijima, Kenji Ishikura, Hiroshi Hataya, Midori Awazu, Mayumi Sako, Masataka Honda, Norishige Yoshikawa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Even in children with mild immunoglobulin (Ig)A nephropathy (IgA-N) showing minimal/focal mesangial proliferation, persistent proteinuria seems to be a risk factor for progression of the disease, indicating the need for an effective and safe treatment even in such cases. Studies carried out to date have indicated that angiotensin-converting enzyme inhibitors (ACEIs) reduce urinary protein excretion and preserve renal function in adult IgA-N. However, no prospective study of ACEI only for childhood IgA-N has yet been carried out. In this prospective single-arm pilot trial, we administered lisinopril (0.4 mg/kg per day) as therapeutic treatment to 40 children with mild IgA-N with proteinuria [morning urinary protein/creatinine ratio (uP/Cr) ≥ 0.2 g/g]. Thirty-three patients reached the primary endpoint (uP/Cr < 0.2) during the 2-year treatment period. The cumulative disappearance rate of proteinuria determined by the Kaplan-Meier method was 80.9%. Mean uP excretion was reduced from 0.40 to 0.18 g/m2/day (p < 0.0001). Of the 40 patients treated, five (12.5%) showed dizziness, and four of these five needed the lisinopril dose reduced. However, lisinopril therapy was continued in all patients during the 2-year treatment period. No other side effect, such as cough, was observed. We conclude that the efficacy and safety of lisinopril is seemingly acceptable for the treatment of children with mild IgA-N.

Original languageEnglish
Pages (from-to)845-849
Number of pages5
JournalPediatric Nephrology
Volume24
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Lisinopril
Immunoglobulin A
Safety
Proteinuria
Angiotensin-Converting Enzyme Inhibitors
Therapeutics
Creatinine
IGA Glomerulonephritis
Proteins
Dizziness
Cough
Disease Progression
Prospective Studies

Keywords

  • Angiotensin-converting enzyme inhibitor
  • Focal mesangial proliferation
  • Minimal change
  • Proteinuria
  • Renin-angiotensin system
  • Urinary protein excretion
  • Urinary protein to creatinine ratio

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Nakanishi, K., Iijima, K., Ishikura, K., Hataya, H., Awazu, M., Sako, M., ... Yoshikawa, N. (2009). Efficacy and safety of lisinopril for mild childhood IgA nephropathy: A pilot study. Pediatric Nephrology, 24(4), 845-849. https://doi.org/10.1007/s00467-008-1006-8

Efficacy and safety of lisinopril for mild childhood IgA nephropathy : A pilot study. / Nakanishi, Koichi; Iijima, Kzumoto; Ishikura, Kenji; Hataya, Hiroshi; Awazu, Midori; Sako, Mayumi; Honda, Masataka; Yoshikawa, Norishige.

In: Pediatric Nephrology, Vol. 24, No. 4, 2009, p. 845-849.

Research output: Contribution to journalArticle

Nakanishi, K, Iijima, K, Ishikura, K, Hataya, H, Awazu, M, Sako, M, Honda, M & Yoshikawa, N 2009, 'Efficacy and safety of lisinopril for mild childhood IgA nephropathy: A pilot study', Pediatric Nephrology, vol. 24, no. 4, pp. 845-849. https://doi.org/10.1007/s00467-008-1006-8
Nakanishi, Koichi ; Iijima, Kzumoto ; Ishikura, Kenji ; Hataya, Hiroshi ; Awazu, Midori ; Sako, Mayumi ; Honda, Masataka ; Yoshikawa, Norishige. / Efficacy and safety of lisinopril for mild childhood IgA nephropathy : A pilot study. In: Pediatric Nephrology. 2009 ; Vol. 24, No. 4. pp. 845-849.
@article{e14b2b77fe924977bd7336ccbf387843,
title = "Efficacy and safety of lisinopril for mild childhood IgA nephropathy: A pilot study",
abstract = "Even in children with mild immunoglobulin (Ig)A nephropathy (IgA-N) showing minimal/focal mesangial proliferation, persistent proteinuria seems to be a risk factor for progression of the disease, indicating the need for an effective and safe treatment even in such cases. Studies carried out to date have indicated that angiotensin-converting enzyme inhibitors (ACEIs) reduce urinary protein excretion and preserve renal function in adult IgA-N. However, no prospective study of ACEI only for childhood IgA-N has yet been carried out. In this prospective single-arm pilot trial, we administered lisinopril (0.4 mg/kg per day) as therapeutic treatment to 40 children with mild IgA-N with proteinuria [morning urinary protein/creatinine ratio (uP/Cr) ≥ 0.2 g/g]. Thirty-three patients reached the primary endpoint (uP/Cr < 0.2) during the 2-year treatment period. The cumulative disappearance rate of proteinuria determined by the Kaplan-Meier method was 80.9{\%}. Mean uP excretion was reduced from 0.40 to 0.18 g/m2/day (p < 0.0001). Of the 40 patients treated, five (12.5{\%}) showed dizziness, and four of these five needed the lisinopril dose reduced. However, lisinopril therapy was continued in all patients during the 2-year treatment period. No other side effect, such as cough, was observed. We conclude that the efficacy and safety of lisinopril is seemingly acceptable for the treatment of children with mild IgA-N.",
keywords = "Angiotensin-converting enzyme inhibitor, Focal mesangial proliferation, Minimal change, Proteinuria, Renin-angiotensin system, Urinary protein excretion, Urinary protein to creatinine ratio",
author = "Koichi Nakanishi and Kzumoto Iijima and Kenji Ishikura and Hiroshi Hataya and Midori Awazu and Mayumi Sako and Masataka Honda and Norishige Yoshikawa",
year = "2009",
doi = "10.1007/s00467-008-1006-8",
language = "English",
volume = "24",
pages = "845--849",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of lisinopril for mild childhood IgA nephropathy

T2 - A pilot study

AU - Nakanishi, Koichi

AU - Iijima, Kzumoto

AU - Ishikura, Kenji

AU - Hataya, Hiroshi

AU - Awazu, Midori

AU - Sako, Mayumi

AU - Honda, Masataka

AU - Yoshikawa, Norishige

PY - 2009

Y1 - 2009

N2 - Even in children with mild immunoglobulin (Ig)A nephropathy (IgA-N) showing minimal/focal mesangial proliferation, persistent proteinuria seems to be a risk factor for progression of the disease, indicating the need for an effective and safe treatment even in such cases. Studies carried out to date have indicated that angiotensin-converting enzyme inhibitors (ACEIs) reduce urinary protein excretion and preserve renal function in adult IgA-N. However, no prospective study of ACEI only for childhood IgA-N has yet been carried out. In this prospective single-arm pilot trial, we administered lisinopril (0.4 mg/kg per day) as therapeutic treatment to 40 children with mild IgA-N with proteinuria [morning urinary protein/creatinine ratio (uP/Cr) ≥ 0.2 g/g]. Thirty-three patients reached the primary endpoint (uP/Cr < 0.2) during the 2-year treatment period. The cumulative disappearance rate of proteinuria determined by the Kaplan-Meier method was 80.9%. Mean uP excretion was reduced from 0.40 to 0.18 g/m2/day (p < 0.0001). Of the 40 patients treated, five (12.5%) showed dizziness, and four of these five needed the lisinopril dose reduced. However, lisinopril therapy was continued in all patients during the 2-year treatment period. No other side effect, such as cough, was observed. We conclude that the efficacy and safety of lisinopril is seemingly acceptable for the treatment of children with mild IgA-N.

AB - Even in children with mild immunoglobulin (Ig)A nephropathy (IgA-N) showing minimal/focal mesangial proliferation, persistent proteinuria seems to be a risk factor for progression of the disease, indicating the need for an effective and safe treatment even in such cases. Studies carried out to date have indicated that angiotensin-converting enzyme inhibitors (ACEIs) reduce urinary protein excretion and preserve renal function in adult IgA-N. However, no prospective study of ACEI only for childhood IgA-N has yet been carried out. In this prospective single-arm pilot trial, we administered lisinopril (0.4 mg/kg per day) as therapeutic treatment to 40 children with mild IgA-N with proteinuria [morning urinary protein/creatinine ratio (uP/Cr) ≥ 0.2 g/g]. Thirty-three patients reached the primary endpoint (uP/Cr < 0.2) during the 2-year treatment period. The cumulative disappearance rate of proteinuria determined by the Kaplan-Meier method was 80.9%. Mean uP excretion was reduced from 0.40 to 0.18 g/m2/day (p < 0.0001). Of the 40 patients treated, five (12.5%) showed dizziness, and four of these five needed the lisinopril dose reduced. However, lisinopril therapy was continued in all patients during the 2-year treatment period. No other side effect, such as cough, was observed. We conclude that the efficacy and safety of lisinopril is seemingly acceptable for the treatment of children with mild IgA-N.

KW - Angiotensin-converting enzyme inhibitor

KW - Focal mesangial proliferation

KW - Minimal change

KW - Proteinuria

KW - Renin-angiotensin system

KW - Urinary protein excretion

KW - Urinary protein to creatinine ratio

UR - http://www.scopus.com/inward/record.url?scp=61549092219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549092219&partnerID=8YFLogxK

U2 - 10.1007/s00467-008-1006-8

DO - 10.1007/s00467-008-1006-8

M3 - Article

C2 - 18825420

AN - SCOPUS:61549092219

VL - 24

SP - 845

EP - 849

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 4

ER -